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not be underestimated. The “antibiotic horse has bolted”, but social
media may help rein the horse back in.
http://dx.doi.org/10.1016/j.ijid.2014.03.579
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Antifungal stewardship
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Antimicrobial stewardship has overwhelmingly focussed on
antibiotics while antifungal agents have been largely neglected
despite data of antifungal drug use showing clear deﬁciencies
in prescribing behaviour. Antifungal stewardship refers to coor-
dinated interventions designed to improve and measure the
appropriate use of antifungals by promoting the selection of
the optimal antifungal drug regimen, dose, duration of therapy,
and route of administration. Antifungal stewards seek to achieve
optimal clinical outcomes related to antimicrobial use, minimize
toxicity and other adverse events, reduce the costs of health care
for infections, and limit the selection for antifungal resistant strains.
The high mortality and morbidity associated with IFDs, including
adverse impact on curative chemotherapy, combined with subop-
timal diagnostic tools, has driven the overuse of antifungal drugs.
Deescalation of empiric therapy is one of the most challenging
aspects of antifungal stewardship to implement. Nonculture-based
tests may enhance antifungal stewardship, but reﬁnement of both
target populations and clinical pathways incorporating their use
is required. Performance indicators including structural, process
and outcome measures are integral for demonstrating the value of
antifungal stewardship programmes. Pharmacy costs inclusive of
antifungal agents are a major determinant of IFD-attributable hos-
pital cost. High drug costs and the toxicities of antifungal agents are
the principal rationale for antifungal stewardship while antifungal
resistance is an emerging but less prevalent issue. The primary goal
is therefore to optimize clinical outcome while minimizing unin-
tended consequences of antifungal drug use followed by reduction
of health care costs displaying a secondary goal. New antifungals
have slight differences in the spectrum of action, dose required,
route of administration, and interactions with other drugs, which
are difﬁcult to manage by a non-fungal specialist. Practice guide-
lines adapted to the local context are the cornerstone of antifungal
stewardship. Local epidemiology informs the choice of antifungal
agents for the prevention and management of IFDs, underscoring
the need for surveillance. Adherence tominimum standards of pre-
scribing ensures that clinical outcomes are optimized and drug
toxicities minimized, thus meeting healthcare quality and safety
goals.
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Resource limited hospitals and unregulated healthcare sett-
ings pose a serious challenge for implementing antimicrobial
stewardship. Lack of trained ID physicians, clinical pharmacists,
epidemiologists, paucity of local microbiology surveillance data
and over the counter availability of broad spectrum antibiotics
makes the implementation of a. formulary restriction and pre-
authorization b. audit, intervention and feedback – which are the
two primary strategies of AMS as highlighted by IDSA guidelines,
very difﬁcult in a hospital. ‘Think Global, Act Local’ is the mantra
for such settings which need indigenous solutions with customiza-
tion of the global guidelines. Formation of clinical pathways and
infection-site speciﬁc guidelines for the hospital which would be
based on local microbiology data was the cornerstone of the AMS
programme started by MSD Pharmaceuticals in India in the year
2008which has now expanded tomany other countries like Russia,
Colombia, Vietnam and Philippines. Clinical pathways and guide-
lines based on local microbiology and resistance patterns is also
given the highest recommendation of AI in the IDSA AMS guide-
lines. In order to fortify this approach further, we decided to
incorporate the supplemental strategies which have got level A
recommendation in the IDSA guidelines, namely Education (AIII),
De-escalation (AII), and Dose optimization (AII).
The site speciﬁc, local microbiology data based antibiotic pro-
tocols/guidelines had 4 basic principles: a. appropriate empirical
antibiotic to be recommended depending on the site of infection
and hospital’s own antibiogram b. the risk stratiﬁcation for the
presence of multi-drug resistant (MDR) pathogens to be taken into
consideration alongwith localmicrobiology for deciding on empir-
ical antibiotic c. de-escalation options based on the culture and
sensitivity results and the patient’s clinical condition to be rec-
ommended d. dose optimization of antibiotics using principles of
pharmacokinetics and pharmacodynamics to be emphasized. Crit-
ical care physicians, Intensivists, Internists with good knowledge
and interest in antibiotics were entrusted with leading the AMS
in the hospital along with the clinical microbiologists. These unit
level champions had the liberty to involve other important decision
makers in the hospital for eg:medical superintendent, the surgeon.
So in most cases a team comprising of 4-5 decision makers was
responsible for rolling out AMS in the hospital. The main strengths
of this local protocol/guideline based AMS model are the follow-
ing a. this is a ‘democratic’ way of implementing AMS in a hospital
which not only aids easy adherence and compliance but also fos-
ters the practice of evidence based medicine very seamlessly b. the
protocol offers solutions tomany commonly confronted clinical sit-
uations related to antibiotic decisions, for eg: when and what to
de-escalate, how to manage multi-drug resistant superbugs, how
to use pk-pd principles to optimize dose etc. Since in most hospi-
tals clinical pharmacists and trained ID physicians are not available
to provide expert opinion on these critical clinical decisions on
antibiotics, in such scenario the protocol booklets acts as a ready
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reckoner. Antimicrobial stewardship is the need of the hour and
every hospital irrespective of its size, scale or resource status must
adopt AMS. I believe that the model of AMS discussed here offers
a viable solution to implement AMS in a resource limited setting.
The clinical and cost outcome measures in the coming years will
further establish the full utility of this model in the hospital setup.
http://dx.doi.org/10.1016/j.ijid.2014.03.581
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The World Health Assembly’s adoption of the Decade of Vac-
cines and the Global Vaccine Action Plan (GVAP) provides us with a
global mandate to accelerate the introduction of new vaccines into
developing countries, with an emphasis on previously neglected
diseases. The remarkable success in the development and intro-
duction of human papilloma virus vaccines demonstrates that this
can be done, despite the stigma associated with sexually transmit-
ted pathogens. In Australia and the United States there is already
evidence of the impact of the HPV vaccine in reducing the spread
of oncogenic HPV types, as well as signiﬁcant clinical impact on
genital warts. There is now amajor push to introduce HPV vaccines
into theAfrican region supportedby theGlobalAllianceonVaccines
and Immunization (GAVI)whichhasnegotiatedmassive reductions
in vaccine prices. Pilot studies have been successfully undertaken
in Uganda and Tanzania, and Rwanda has successfully introduced
the vaccine with South Africa committed to do this in 2014. This
talk will address the many questions that African countries need to
considerwhen introducingHPV vaccines: age group, girls and boys,
programmatic decisions including where to immunize and dosing
schedules, and will consider what the potential long term impact
of these vaccines could be on the epidemiology of HPV within the
region.
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Gonorrhoea remains a common sexually transmitted infection
and enhances both the transmission and acquisition of HIV in high
prevalence settings. The capacity to treat, and thereby control,
gonorrhoea diminishes as antimicrobial resistance (AMR) wors-
ens. Enhanced efforts are urgently required to reduce the global
burden of gonorrhoea and simultaneous sustained AMR contain-
ment measures are also needed to limit antimicrobial misuse. Both
approaches are critical for reducing the rate of emergence and
spread of AMR determinants to Neisseria gonorrhoeae. Expanded
surveillance of gonococcal AMR, urgently needed for provision
of valid data worldwide, has been initiated by the World Health
Organization and various national public health laboratories. These
surveillance programmes may identify the emergence and trans-
mission of novel AMR-associated N. gonorrhoeae strains. They
also provide the evidence base to update STI management and
treatment guidelines. In the absence of AMR surveillance, many
countries continue to use old antimicrobial agents without any
idea as to current drug efﬁcacy. Critically, within the context
of gonorrhoea control, decreased susceptible N. gonorrhoeae iso-
lates displaying elevated minimum inhibitory concentrations to
the extended spectrum cephalosporins are now being identiﬁed
in many countries. However, the imprecise nature of laboratory
criteria for detecting these gonococci means that the distribution
and prevalence of these strains, as well as multi drug-resistant
(MDR)andextensivelydrug-resistant (XDR)N. gonorrhoeae, remain
uncertain. The availability and affordability of high quality efﬁca-
cious antimicrobial agents in all settings and countries is essential.
Achieving this goal will be difﬁcult but failure to do so will
only accelerate the spread of existing MDR-NG and the further
emergence of XDR-NG. Finally, given the challenge of achieving
sustained sexual behaviour change, research initiatives to develop
an effective vaccine for gonorrhoea are crucial in an era of reduced
research funding and must be prioritized.
http://dx.doi.org/10.1016/j.ijid.2014.03.583
